INmune Bio Inc
Research INmune Bio Inc (INMB) on Bullrun: market cap USD 67.20M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINMB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 67.20M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 1.27M
- Free cash flow-USD 3.61M
Valuation Snapshot
latest market cap is USD 67.20M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 50.00K | -USD 46.00M | -USD 23.62M | n/a | -1.86 | USD 24.75M | USD 1.03M | USD 23.52M |
| FY2024 | USD 14.00K | -USD 42.00M | -USD 33.36M | n/a | -2.11 | USD 20.92M | USD 15.00M | USD 32.10M |
| FY2023 | USD 155.00K | -USD 30.00M | n/a | n/a | -1.67 | USD 35.85M | USD 9.92M | USD 37.34M |
| FY2022 | USD 374.00K | -USD 27.30M | n/a | n/a | -1.52 | USD 52.15M | USD 14.70M | USD 60.10M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 67.20M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 41.47M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 104.05M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 202.68M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 113.78M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 182.00M | n/a | n/a | n/a |
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is INmune Bio Inc's market cap?
INmune Bio Inc's market capitalization is USD 67.20M.
What does INmune Bio Inc do?
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer.